| Autor: |
Yuan-Yuan Yong, Li Zhang, Yu-Jiao Hu, Jian-Ming Wu, Lu Yan, Yi-Ru Pan, Yong Tang, Lu Yu, Betty Yuen-Kwan Law, Chong-Lin Yu, Jie Zhou, Mao Li, Da-Lian Qin, Xiao-Gang Zhou, An-Guo Wu |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Clinical Immunology. 244:109093 |
| ISSN: |
1521-6616 |
| DOI: |
10.1016/j.clim.2022.109093 |
| Popis: |
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging evidence indicates that the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is activated, which results in a cytokine storm at the late stage of COVID-19. Autophagy regulation is involved in the infection and replication of SARS-CoV-2 at the early stage and the inhibition of NLRP3 inflammasome-mediated lung inflammation at the late stage of COVID-19. Here, we discuss the autophagy regulation at different stages of COVID-19. Specifically, we highlight the therapeutic potential of autophagy activators in COVID-19 by inhibiting the NLRP3 inflammasome, thereby avoiding the cytokine storm. We hope this review provides enlightenment for the use of autophagy activators targeting the inhibition of the NLRP3 inflammasome, specifically the combinational therapy of autophagy modulators with the inhibitors of the NLRP3 inflammasome, antiviral drugs, or anti-inflammatory drugs in the fight against COVID-19. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect